These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 22833955)

  • 21. Rapid single-nucleotide polymorphism detection of cytochrome P450 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genes for the warfarin dose adjustment by the SMart-amplification process version 2.
    Aomori T; Yamamoto K; Oguchi-Katayama A; Kawai Y; Ishidao T; Mitani Y; Kogo Y; Lezhava A; Fujita Y; Obayashi K; Nakamura K; Kohnke H; Wadelius M; Ekström L; Skogastierna C; Rane A; Kurabayashi M; Murakami M; Cizdziel PE; Hayashizaki Y; Horiuchi R
    Clin Chem; 2009 Apr; 55(4):804-12. PubMed ID: 19181737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Building individualized medicine: prevention of adverse reactions to warfarin therapy.
    Krynetskiy E; McDonnell P
    J Pharmacol Exp Ther; 2007 Aug; 322(2):427-34. PubMed ID: 17496169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Vitamin K epoxide reductase: Fresh blood for oral anticoagulant therapies].
    Loriot MA; Beaune P
    Rev Med Interne; 2006 Dec; 27(12):979-82. PubMed ID: 17070618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fundamental Considerations for Genetically-Guided Pain Management with Opioids Based on CYP2D6 and OPRM1 Polymorphisms.
    Ruano G; Kost JA
    Pain Physician; 2018 Nov; 21(6):E611-E621. PubMed ID: 30508992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adverse drug reaction monitoring in Jena. Relevance of polymorphic drug metabolizing enzymes for inducing adverse drug reactions.
    Hippius M; Buchardt C; Farker K; Kuhn UD; Reimann IR; Hoffmann A
    Exp Toxicol Pathol; 2003 Jun; 54(5-6):417-21. PubMed ID: 12877354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Taking personalized medicine to heart.
    Nat Med; 2018 Feb; 24(2):113. PubMed ID: 29414928
    [No Abstract]   [Full Text] [Related]  

  • 27. Personalized Cardiovascular Medicine Today: A Food and Drug Administration/Center for Drug Evaluation and Research Perspective.
    Blaus A; Madabushi R; Pacanowski M; Rose M; Schuck RN; Stockbridge N; Temple R; Unger EF
    Circulation; 2015 Oct; 132(15):1425-32. PubMed ID: 26459078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness.
    Linares OA; Daly D; Linares AD; Stefanovski D; Boston RC
    Pain Med; 2014 May; 15(5):791-806. PubMed ID: 24517173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenetic testing for warfarin sensitivity.
    Lyon E; McMillin G; Melis R
    Clin Lab Med; 2008 Dec; 28(4):525-37. PubMed ID: 19059060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Genetic polymorphism of CYP-450 in drug development].
    Nonen S; Azuma J
    Nihon Yakurigaku Zasshi; 2009 Oct; 134(4):212-5. PubMed ID: 19828926
    [No Abstract]   [Full Text] [Related]  

  • 31. An innovative software solution for personalized pharmacotherapy.
    Garson L; Bruns B
    Ther Deliv; 2010 Nov; 1(5):643-50. PubMed ID: 22833954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lessons from Cuba for Global Precision Medicine: CYP2D6 Genotype Is Not a Robust Predictor of CYP2D6 Ultrarapid Metabolism.
    Dorado P; González I; Naranjo ME; de Andrés F; Peñas-Lledó EM; Calzadilla LR; LLerena A
    OMICS; 2017 Jan; 21(1):17-26. PubMed ID: 28271978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenomics for personalized pain medicine.
    Ko TM; Wong CS; Wu JY; Chen YT
    Acta Anaesthesiol Taiwan; 2016 Mar; 54(1):24-30. PubMed ID: 26976339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CYP450 Genotype/Phenotype Concordance in Mexican Amerindian Indigenous Populations-Where to from Here for Global Precision Medicine?
    de Andrés F; Sosa-Macías M; Ramos BPL; Naranjo MG; LLerena A
    OMICS; 2017 Sep; 21(9):509-519. PubMed ID: 28873029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Special Review: Caught in the Crosshairs: Targeted Drugs and Personalized Medicine.
    Ferreira BI; Hill R; Link W
    Cancer J; 2015; 21(6):441-7. PubMed ID: 26588674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in the product label for pimozide illustrate both the promises and the challenges of personalized medicine.
    Preskorn SH
    J Clin Psychiatry; 2012 Sep; 73(9):1191-3. PubMed ID: 23059147
    [No Abstract]   [Full Text] [Related]  

  • 37. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.
    Halling J; Petersen MS; Damkier P; Nielsen F; Grandjean P; Weihe P; Lundgren S; Lundblad MS; Brøsen K
    Eur J Clin Pharmacol; 2005 Aug; 61(7):491-7. PubMed ID: 16025294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medicine: K is for koagulation.
    Sadler JE
    Nature; 2004 Feb; 427(6974):493-4. PubMed ID: 14765176
    [No Abstract]   [Full Text] [Related]  

  • 39. Personalized Medicine: Pharmacogenomics and Drug Development.
    Mirsadeghi S; Larijani B
    Acta Med Iran; 2017 Mar; 55(3):150-165. PubMed ID: 28282716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular Dynamics: New Frontier in Personalized Medicine.
    Sneha P; Doss CG
    Adv Protein Chem Struct Biol; 2016; 102():181-224. PubMed ID: 26827606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.